{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T02:55:00Z","timestamp":1764557700937,"version":"3.40.5"},"reference-count":16,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:00:00Z","timestamp":1699660800000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In Australia, over half of patients with relapsed\/refractory chronic lymphocytic leukaemia treated with ibrutinib use concomitant proton pump inhibitors (PPIs). High gastric pH reduces the bioavailability of some Bruton tyrosine kinase inhibitors. There was no difference in duration on ibrutinib with or without concomitant PPI (unadjusted <jats:italic>P<\/jats:italic> =\u20090.61; adjusted hazard ratio: 1.23, 95% confidence interval: 0.75\u20132.02, <jats:italic>P<\/jats:italic> =\u20090.411). PPI use does not affect ibrutinib treatment persistence.<\/jats:p>","DOI":"10.1111\/imj.16267","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T11:08:38Z","timestamp":1699700918000},"page":"2115-2118","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Australian data on the utilisation and duration on treatment of ibrutinib with a proton pump inhibitor in patients with relapsed or refractory chronic lymphocytic leukaemia"],"prefix":"10.1111","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1053-5503","authenticated-orcid":false,"given":"Ross","family":"Salvaris","sequence":"first","affiliation":[{"name":"Sir Charles Gairdner Hospital  Perth Western Australia Australia"},{"name":"University of Western Australia  Perth Western Australia Australia"},{"name":"Monash University  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1928-2098","authenticated-orcid":false,"given":"Stephen","family":"Mulligan","sequence":"additional","affiliation":[{"name":"Royal North Shore Hospital  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7730-6310","authenticated-orcid":false,"given":"Andrea","family":"Puig","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag Pty Ltd  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5554-0253","authenticated-orcid":false,"given":"Marija","family":"McGeachie","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag Pty Ltd  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0308-6458","authenticated-orcid":false,"given":"Stephen","family":"Opat","sequence":"additional","affiliation":[{"name":"Monash Health  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,11,11]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30051-1"},{"key":"e_1_2_4_3_1","unstructured":"Janssen Australia.Australian Product Information Imbruvica\u00ae (ibrutinib) Capsules And Tablets; 2022. Available from URL:https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2015-PI-01676-1&d=20220705172310101"},{"key":"e_1_2_4_4_1","unstructured":"AstraZeneca Australia.Calquence\u00ae (acalabrutinib) Capsules Australian Product Information; 2019. Available from URL:https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2019-PI-02285-1&d=20220704172310101"},{"key":"e_1_2_4_5_1","unstructured":"BeiGene AUS.Australian Product Information Brukinsa (zanubrutinib); 2021. Available from URL:https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2021-PI-02239-1"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25638"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18306"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.13739"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp400403s"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31917"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1588.1588"},{"key":"e_1_2_4_13_1","first-page":"439","article-title":"A review of the Bruton tyrosine kinase inhibitors in B\u2010cell malignancies","volume":"12","author":"Moore DC","year":"2021","journal-title":"J Adv Pract Oncol"},{"key":"e_1_2_4_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12948"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-015-1616-8"},{"key":"e_1_2_4_16_1","doi-asserted-by":"publisher","DOI":"10.17061\/phrp2541546"},{"volume-title":"The Fourth Australian Atlas of Healthcare Variation","year":"2021","key":"e_1_2_4_17_1"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.16267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T10:12:13Z","timestamp":1702116733000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.16267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1111\/imj.16267"],"URL":"https:\/\/doi.org\/10.1111\/imj.16267","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"type":"print","value":"1444-0903"},{"type":"electronic","value":"1445-5994"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"2023-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}